Interferon-gamma gene therapy

Drug Profile

Interferon-gamma gene therapy

Latest Information Update: 15 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiron Technologies; Nonindustrial source
  • Developer Chiron Corporation; Chiron Technologies; Nonindustrial source
  • Class Cytokine genes; Gene therapies; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant melanoma; Neuroblastoma

Most Recent Events

  • 16 Dec 1998 A clinical study was added to the therapeutic trials section
  • 03 Sep 1997 Phase-II clinical trials for Malignant melanoma in USA (Injection)
  • 27 Sep 1996 Phase-I clinical trials for Malignant melanoma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top